Press release
Global Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022
Xifaxan And Viberzi To Give Facelift To The Global Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022The latest market report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 1,115.06 Mn by 2022, expanding at a CAGR of 13.89% from 2016 to 2022.
Browse the full report Irritable Bowel Syndrome with Diarrhea (IBS-D) 2016–2022 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market
Market Insights
IBS affects between 10% to 20% individuals in the developed countries. Since the underlying cause of IBD remains unknown, the treatment market for the same is observed to be unvisited and is characterized by very few indicated drugs. By far, alosetron has been the only drug approved for IBS-D treatment. With the approval for eluxadoline (Viberzi) and rifaximin (Xifaxan), new avenues in the IBS-D treatment market have opened, giving hopes to the patients.
Both Viberzi and Xifaxan are determined to be safe, Viberzi may receive controlled substance label due to risk of potential abuse. Viberzi and other IBS-D drugs act on opioid receptors, thus it is a mu receptor antagonist and kappa receptor antagonist. On the other hand, Xifaxan is viewed as a curative regimen, since it acts by altering the bacterial flora in the guts.
For More Reports Related to This Category @ http://www.credenceresearch.com/industry/pharmaceuticals-market
Xifaxan has been reportedly prescribed off label for treating IBS-D. Its formal sanction will thus support the growth in demand for the drug in the forecast period. Xifaxan is prescribed for a 14 day, thrice a day dosage; with a further additional 1 week dosage if the need arises. However, its long term role in efficiently containing IBS-D is still questioned. Viberzi, on the other hand, easily fits the profile of everyday medication for chronic disease treatment, similar to diabetes and CVD treatments. Further safety and effective assessments on these drugs are lined up, which will clear the market status of the two drugs.
The market for Viberzi is expected to cross USD 6 Mn mark by 2022, whereas Xifaxan market is expected to progress at a CAGR of moderate 4.46% during 2016-2022. IBS-D affects over 15 million Americans, with no single drugs having a clear domination in the market. Loperamide, angidepressants, alosetron, bile acid binders and similar such drugs were the standard treatments in the past. Medical professionals have largely relied on trial and error approach for treating IBS-D patients.
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022 here
News-ID: 336213 • Views: …
More Releases from credence research

Pharmacy Market Size, Growth | Industry Report, 2023-2032
The latest market report published by Credence Research, Inc. The demand for the US Retail Pharmacy Market, valued at USD 569.79 Billion in 2023, is projected to soar to USD 948.80 Billion by 2032, marking a robust compound annual growth rate (CAGR) of 5.76% during the period from 2024 to 2032.
The US retail pharmacy market stands as a cornerstone of the nation's healthcare infrastructure, serving as the frontline for patient…

Medical Headgears Market is Expected to Reach USD 2,184.62 million by 2032 | Cre …
The Medical Headgears Market is poised for substantial growth, with a market value of USD 1,247.86 million in 2024 projected to surge to USD 2,184.62 million by 2032, representing a robust compound annual growth rate (CAGR) of 6.36%.
In the realm of healthcare, innovation is key, and this holds true for the field of medical headgears. These devices play a crucial role in various medical applications, from orthodontics to craniofacial…

Quality Management Software Market Size, Share, Analysis, Growth & Forecast 2030
The latest market report published by Credence Research, Inc. The global demand for Quality Management Software market was valued at USD 9654.8 Million in 2023 and is expected to reach USD 24697.3 Million in 2032, growing at a CAGR of 11.00% between 2024 and 2032.
In today's fast-paced and highly competitive business landscape, ensuring the highest level of product or service quality is paramount. Quality management is not just a goal…

Commercial Drone Market Size, Growth to Reach USD 56756.3 Million by 2030 | Cred …
The latest market report published by Credence Research, Inc. The global demand for Commercial Drone was valued at USD 19482.5 Million in 2022 and is expected to reach USD 56756.3 Million in 2030, growing at a CAGR of 14.30% between 2023 and 2030.
In recent years, the commercial drone market has experienced exponential growth, revolutionizing industries and opening up new possibilities for businesses across the globe. From agriculture and construction to…
More Releases for IBS
Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs.
👉 Download our latest market insights:…
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR…
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA…
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide.
A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L…
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning.
This also includes consulting services concerning railway systems issues, such as travel…
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011.
The new bulkers, each with a capacity of 176,000 dwt, will be equipped…